Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals
Epic: APH
News: Latest news
Web Site: Alliance Pharma
Other Articles: 22-06-201027-05-201007-05-2010 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday July 29, 09:30Specialist Energy Group Lays Out a Compelling Blueprint for Growth

After a difficult start to life as a stock market listed company, the company now stands at the threshold of a much brighter future. Legacy issues have been dealt with and the turnaround programme initiated by CEO Ewan Lloyd-Baker is gaining traction.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive AU ▼

Wednesday July 28, 11:30Silver Lake Resources boosts high grade gold resource by 70% to 2.5m ounces

Silver Lake Resources has added over 1 million ounces of gold to its resource inventory during the year after mining 66,700 ounces and expects further encouraging results at its  Mount Monger and Murchison projects.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive CN ▼

Thursday July 15, 02:10Henan Yuguang Lead & Gold investment in Kimberley Metals receives all clear from FIRB

Kimberley Metals (ASX: KBL) has reported that on 12 July the Australian Government Foreign Investment Review Board (FIRB) had no objections to Henan Yuguang Lead & Gold Co. Ltd's [...]

FULL ARTICLE ►
Alliance Pharma

Alliance Pharma

Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.

CLICK HERE FOR FULL ANLAYSIS OF ALLIANCE PHARMA
Wednesday, March 17, 2010

Alliance Pharma completes transfer of Xenazine and Nitoman distribution agreement

Alliance Pharma (AIM: APH) told investors that it has completed the transfer of a distribution agreement with Biovail Laboratories for the tetrabenazine drug, part of the recently acquired Cambridge Laboratories portfolio. Under the terms of the acquisition, completed in February, the product’s transfer was deferred subject to the successful transfer of the distribution deal.

The tetrabenazine drug, marketed under the Xenazine and Nitoman brand names, is approved for use in the United Kingdom and the Republic of Ireland in connection with chorea associated with Huntington's Disease, tardive dyskinesia and certain other indications. A chorea is an abnormal involuntary movement disorder.

The benefit of the distribution agreement was been transferred to Alliance on 16 March 2010, and consequently, £1.5m of the deferred consideration will now be paid to Cambridge Laboratories as the vendors.

The new distribution agreement also conditionally provides for Alliance to be appointed as distributor of new formulations of tetrabenazine that are developed, including, potentially, a modified-release formulation that is currently in development for Tourette's Syndrome in 5-16 year old children.

Through the Cambridge Laboratories acquisition, Alliance gained a portfolio of 18 prescription products across a broad range of therapeutic areas include oncology, toxicology and others. When the deal was completed in February, the company said it expects the deal to be significantly earnings enhancing in the current financial year.

In commercial terms, Cambridge’s key products are primarily in the oncology area. The ImmuCyst product is an immunotherapy for bladder cancer, Procarbazine forms part of a chemotherapy treatment for Hodgkin's Lymphoma and its Gelclair product is an oral gel used in the management of oral mucositis, which is a side-effect caused by chemotherapy and radiotherapy. The portfolio also includes a toxicology product which is contracted for a UK government stockpile, and is replaced on a 2-3 year cycle.  Cambridge’s existing £5.6m contract runs from October 2009 to January 2011.

AddThis Feed Button
Register here to be notified of future Alliance Pharma articles.

Other Alliance Pharma news

More news ►

Investors interested in Alliance Pharma recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.